TY - JOUR T1 - Phylogenetic estimates of SARS-CoV-2 introductions into Washington State JF - medRxiv DO - 10.1101/2021.04.05.21254924 SP - 2021.04.05.21254924 AU - Diana M. Tordoff AU - Alexander L. Greninger AU - Pavitra Roychoudhury AU - Lasata Shrestha AU - Hong Xie AU - Keith R. Jerome AU - Nathan Breit AU - Meei-Li Huang AU - Mike Famulare AU - Joshua T. Herbeck Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254924.abstract N2 - Background The first confirmed case of SARS-CoV-2 in North America was identified in Washington state on January 21, 2020. We aimed to quantify the number and temporal trends of out-of-state introductions of SARS-CoV-2 into Washington.Methods We conducted a phylogenetic analysis of 11,422 publicly available whole genome SARS-CoV-2 sequences from GISAID sampled between December 2019 and September 2020. We used maximum parsimony ancestral state reconstruction methods on time-calibrated phylogenies to enumerate introductions/exports, their likely geographic source (e.g. US, non-US, and between eastern and western Washington), and estimated date of introduction. To incorporate phylogenetic uncertainty into our estimates, we conducted 5,000 replicate analyses by generating 25 random time-stratified samples of non-Washington reference sequences, 20 random polytomy resolutions, and 10 random resolutions of the reconstructed ancestral state.Results We estimated a minimum 287 separate introductions (median, range 244-320) into Washington and 204 exported lineages (range 188-227) of SARS-CoV-2 out of Washington. Introductions began in mid-January and peaked on March 29, 2020. Lineages with the Spike D614G variant accounted for the majority (88%) of introductions. Overall, 61% (range 55-65%) of introductions into Washington likely originated from a source elsewhere within the US, while the remaining 39% (range 35-45%) likely originated from outside of the US. Intra-state transmission accounted for 65% and 28% of introductions into eastern and western Washington, respectively.Conclusions There is phylogenetic evidence that the SARS-CoV-2 epidemic in Washington is continually seeded by a large number of introductions, and that there was significant inter- and intra-state transmission. Due to incomplete sampling our data underestimate the true number of introductions.Competing Interest StatementALG reports personal fees from Abbott Molecular, grants from Merck, grants from Gilead, outside the submitted work. DMT, PR, LS, HX, KRJ, NB, MLH, MF and JTH declare no competing interests.Funding StatementDMT receives support from the NIH National Institute of Allergy And Infectious Diseases (F31AI152542). JTH and DMT also receive support from the NIH National Institute of Allergy and Infectious Disease (R01AI127232). Funders had no role in study design, collection, analysis, and interpretation of data, writing of the report, or the decision to submit the paper for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of residual clinical specimens for sequencing was approved by the institutional review board at the University of Washington with a waiver of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available via GISAID at https://www.gisaid.org/. ER -